ena-STUDY-Radboud university medical center, Radboud Institute for Health Sciences-15-03-2017-15:11:11:603-35
TArgeted therapy in Renal cell cancer: GEnetic and Tumour related biomarkers for response and toxicity
The overall aim of EuroTARGET is to identify and characterize host and tumour related predictive biomarkers for response to targeted therapy in patients with (metastasized) renal cell cancer. Our overall concept is to focus on germline genome and tumour transcriptome, methylome and kinome-related biomarkers using an hypothesis-free and integrative approach and to evaluate promising findings via replication and functional assays. The main innovation of the EuroTARGET approach lies in the application and integration of cutting-edge high-throughput methodology and focused functional follow-up studies on relatively large numbers of RCC patient series treated with sorafenib or sunitinib or other targeted drug therapies.
The overall aim of EuroTARGET is to identify and characterize host and tumour related predictive biomarkers for response to targeted therapy in patients with (metastasized) renal cell cancer. Our overall concept is to focus on germline genome and tumour transcriptome, methylome and kinome-related biomarkers using an hypothesis-free and integrative approach and to evaluate promising findings via replication and functional assays. The main innovation of the EuroTARGET approach lies in the application and integration of cutting-edge high-throughput methodology and focused functional follow-up studies on relatively large numbers of RCC patient series treated with sorafenib or sunitinib or other targeted drug therapies.